Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical China

China SFDA Seeks Public Comment On Change To Proposed Definition Of “New” Drugs

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Agency’s draft drug registration rules propose to eliminate China’s fast track approval process for certain types of drugs, including AIDS and oncologics.

You may also be interested in...



Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu

Simcere Pharmaceutical Group plans to be one of the last China-based pharmaceutical firms standing after a predicted major consolidation could shrink that industry to as few as 1,000 companies in the next several years

Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu

Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.

Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu

Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.

Table

View full table

Topics

Tags:
BioPharmaceutical China
UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By